Celularity Inc
For the period ended Dec 31, 2025. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 30, 2026
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Net revenues | ||
| Product sales, net | $13,175 | $35,336 |
| Services | 5,432 | 5,140 |
| License, royalty and other | 7,943 | 13,744 |
| Total revenues | 26,550 | 54,220 |
| Operating expenses | ||
| Cost of revenues (excluding amortization of acquired intangible assets) | ||
| Product sales | 12,853 | 4,924 |
| Services | 859 | 1,172 |
| License, royalty and other | 6,362 | 8,893 |
| Research and development | 15,025 | 17,386 |
| Selling, general and administrative | 51,266 | 58,643 |
| Change in fair value of contingent consideration liability | — | (193) |
| Amortization of acquired intangible assets | 1,493 | 1,753 |
| Total operating expenses | 87,858 | 92,578 |
| Loss from operations | (61,308) | (38,358) |
| Other income (expense): | ||
| Interest income | 262 | 331 |
| Interest expense | (6,754) | (6,264) |
| Change in fair value of warrant liabilities | (3,318) | 398 |
| Change in fair value of derivative liability | 65 | — |
| Change in fair value of debt | (1,809) | (492) |
| Loss on debt extinguishment | (6,356) | (3,908) |
| Amortization of licensing obligation premium | 1,911 | — |
| Loss on issuance of convertible notes with warrants | (2,335) | — |
| Impairment of preferred stock investment | (2,890) | — |
| Compliance fees and other expense, net | (9,181) | (9,599) |
| Total other expense | (30,405) | (19,534) |
| Loss before income taxes | (91,713) | (57,892) |
| Income tax expense (benefit) | 3 | — |
| Net loss | (91,716) | (57,892) |
| Deemed dividend relating to inducement of Dragasac warrants | (64) | — |
| Paid-in kind preferred stock dividend | (20) | — |
| Net loss attributable to common shareholders | $(91,800) | $(57,892) |
| Per share information: | ||
| Net loss per share – basic and diluted | (3.59) | (2.64) |
| Weighted average shares outstanding – basic and diluted | 25,598,586 | 21,890,518 |
| Net loss | $(91,716) | $(57,892) |
| Other comprehensive loss | ||
| Change in fair value of debt due to change in credit risk | 5 | (5) |
| Comprehensive loss | $(91,711) | $(57,897) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.